Navigation Links
Advanced Life Sciences Announces Fourth Quarter and Full Year 2007 Financial Results

d and met with National Advisory Board for Cethromycin consisting

of thought leaders in the area of respiratory tract infections and

antibiotic therapies;

-- Granted Orphan Drug Designation by the FDA for ALS-357 in the topical

treatment of metastatic melanoma; and

-- Advanced development of ALS-357: manufactured clinical supplies and

submitted the protocol to the Northwestern University Institutional

Review Board (IRB) for the planned Phase I/II melanoma program.

Cethromycin Objectives for 2008

-- Attend FDA Anti-Infectives Advisory Committee meeting discussing

non-inferiority margins in CAP clinical trials scheduled for

April 1 and 2, 2008 and provide management's understanding of the

Advisory Committee meeting to investors via conference call on

April 3, 2008.

-- Conduct meeting with FDA on April 7, 2008 to discuss the anticipated

NDA submission in CAP and provide summary of outcome to investors via

conference call on April 10, 2008.

-- Incorporate guidance from April 1-2 FDA Advisory Committee meeting and

April 7 Advanced Life Sciences meeting with FDA to complete NDA

submission activities for cethromycin as a treatment for CAP;

-- Finalize negotiations with potential commercial partners for


-- Continue collaborations with the National Institute of Allergy and

Infectious Diseases (NIAID) and The U.S. Army Medical Research

Institute for Infectious Diseases (USAMRIID) to explore cethromycin's

activity against high-priority bioterror agents for its use as a broad

spectrum countermeasure; and

-- Present cethromycin clinical data at ICAAC in the Fall.

Financial Guidance for 2008

Advanced Life Sciences expects its 2008 cash requirements excluding milestone payments that become due upon NDA filing to f

SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
3. Advanced Cell Technology Announces Proposed Financing
5. Advanced Cell Technologys Dr. Robert Lanza Makes List of 100 Most Inspiring People in the Life-Sciences Industry
6. Advanced Life Sciences to Present at 2007 UBS Global Life Sciences Conference
7. CeloNova BioSciences Announces Worlds First Line of Fully Color-Coded Embolic Particles at CIRSE: Embozene(TM) Color-Advanced Microspheres
8. Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology
9. Advanced Bionics Deploys CEVA-TeakLite(TM) DSP Core to Enhance Its Harmony(TM) HiResolution(R) Bionic Ear System
10. NIH Announces Advanced Cell Technologys Single Cell Embryo Biopsy Technique as a Means to Derive Embryonic Stem Cells to be Considered for Federal Funding
11. Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
Post Your Comments:
(Date:10/8/2015)... 8, 2015 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) ... on the development of autologous cell therapies, today announced its ... taking place in the month of October: ... RepliCel will be presenting at the annual Partnering ... Mesa to be held October 7-9 in ...
(Date:10/8/2015)... ... October 08, 2015 , ... ProMIS Neurosciences, Inc. (TSX: PMN), ... and commercialize intellectual property rights belonging to The University of British Columbia (UBC). ... exclusive worldwide rights to intellectual property based on use of the ProMIS™ technology, ...
(Date:10/7/2015)... ... October 07, 2015 , ... Neil Riordan, PhD to Discuss Medicinal Effects ... 8th, at Mar-a-Lago from 3:50 pm to 4:30 pm. , Dr. Riordan is one ... , He is the Co-Founder and Chief Science Officer of the Riordan-McKenna ...
(Date:10/7/2015)... ORANGEBURG, N.Y. , Oct. 7, 2015   ... solutions, today released an infographic that highlights key challenges ... selecting an appropriate disinfectant for the situation. This tool ... around steps hospitals can take to create efficiencies and ... The visual guide emphasizes examples of how ...
Breaking Biology Technology:
... - Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced ... a clinical trial using intravenous administration of,REOLYSIN(R) ... well as immune modulator, in patients with ... Spicer of King,s College in London,Dr. Johann ...
... (Nasdaq:,ATSI), manufacturer and marketer of state-of-the-art cardiac surgery,products, ... Rodman & Renshaw,5th Annual Global Healthcare Conference at ... on Tuesday, May 20, 2008. Michael Dale, President ... a.m. local time., (Logo: ), ...
... Inc. (OTC,Bulletin Board: PLMO) announced today that it ... taking its total holdings to 61% in this ... for pulmonary,related medical conditions., Pulmo BioTech CEO ... technology, developed and owned by PulmoScience, will dominate ...
Cached Biology Technology:
(Date:9/30/2015)... 30, 2015  With nearly 300,000 Americans living with ... SCIs estimated to reach 12,500 annually, the role of ... Services for Independent Living (SCRS-IL) is increasingly important. ... California opening doors to independence for individuals ... services, notably assistive technology services and education. ...
(Date:9/29/2015)... 2015  iDAvatars is excited to be named one of ... market. The official announcement was recently made at an invite-only ... San Francisco , where iDAvatars presented a ... Watson. "It is both an honor and a ... bring to market the cognitive power of IBM Watson in ...
(Date:9/28/2015)... -- According to a new market research ... & Others), Application (Access Control & Others), Industry (Travel ... Global - Forecast to 2020", published by MarketsandMarkets, the Iris ... by 2020, at a CAGR of 23.40% between 2015 ... T ables and 66 Figures spread ...
Breaking Biology News(10 mins):
... nice piece of certified sustainable fish at the supermarket, you,d ... aren,t always what they seem, according to researchers who have ... report their findings in the August 23 issue of ... found that, for fish purchased in US groceries, not all ...
... 2011, 3:00 PM U.S. EASTERN TIME) A study ... Sciences (PNAS) documents the success of a Wildlife ... to improve rural livelihoods while restoring local wildlife populations., ... began in Zambia in 2003 and has resulted in ...
... Research (ONR) will share partnership possibilities with members of ... Gold Coast Small Business Opportunity Conference, being held Aug. ... to identify potential program participants from among the 1,500 ... Small Business Programs. "The event is a great way ...
Cached Biology News:
... of the smallest thermal cyclers on the market, ... the 0.5ml (20 samples) or 0.2ml microtube (25 ... heating and cooling rate of 3.6C/sec and 2.0C/sec ... Fast track programming with new quick dial ...
... an aqueous solution that contains a purified ... in a MOPS buffer (3-(N-Morpholino) propanesulfonic acid), ... contains a combination of 0.02% methylisothiazolone, 0.02% ... and Haas Company) as a preservative. ...
Preparation Note: Prepared by method of Wimmer, E., et al., Biochemistry, 7, 2623 (1968). Quality Clarifier: Acceptor Activity: approx. 1000 picomoles phenylalanine per A 260 unit (not determined b...
This buffer is Specifically formulated to be used with Endogen's Poly-HRP Streptavidin...
Biology Products: